奈伐庫單抗

化合物

奈伐庫單抗INN:Nesvacumab),或譯奈伐蘇單抗耐斯伐庫單抗,是一種實驗性單克隆抗體,最初設計用於治療癌症。它的靶標是血管生成素2英語Angiopoietin 2[1][2]截至2017年5月,該藥物正處於治療糖尿病性黃斑水腫的II期臨床試驗中。[3][4]該藥物由再生元製藥公司開發。

奈伐庫單抗
單克隆抗體
種類完整抗體
目標血管生成素2英語Angiopoietin 2
臨床資料
ATC碼
  • 未分配
法律規範狀態
法律規範
  • 研究中
識別資訊
CAS號1296818-77-3
IUPHAR/BPS
ChemSpider
  • none
UNII
KEGG
化學資訊
化學式C6440H9966N1722O2008S38
摩爾質量144,860.89 g·mol−1

參考資料

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Nesvacumab頁面存檔備份,存於網際網路檔案館), American Medical Association.
  2. ^ Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA. Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. Expert Opinion on Investigational Drugs. October 2019, 28 (10): 861–869. PMID 31513439. doi:10.1080/13543784.2019.1667333. 
  3. ^ Clinical trial number NCT02713204 for "Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)" at ClinicalTrials.gov
  4. ^ Clinical trial number NCT02712008 for "Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY)" at ClinicalTrials.gov